Company prepares new product launches starting in 2025.

New Survey Shows That Over 90% of Animal Owners Trust and Appreciate Veterinary Teams but Underestimate the Demands of the Profession ...

German pharmaceutical giant Boehringer Ingelheim said China remains a market of continued interest and would keep up the ...

Zoetis, an industry leader in animal health, has seen substantial growth in revenues, EBITDA margins, and market share over the last decade. The company’s profitability, scale, diversity, and reach ...

Auto-brewery syndrome produces symptoms of intoxication when ethanol produced by dysregulated gut microbiota exceeds the ...

CEOs from large pharma companies AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly ... in December made its biggest single investment in China to date, roughly 1 billion euros ($1.08 billion ...

Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or metabolic dysfunction ...

HUBERTUS VON BAUMBACH, CEO, BOEHRINGER INGELHEIM Boehringer Ingelheim China, which employs 4,000 people, focuses on human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

Boehringer Ingelheim’s weight-loss drug candidate ... Boehringer also formed an alliance worth up to $2 billion with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop ...

19-year-old Johannes von Baumbach ($5.4 billion), and 14 other heirs to the Boehringer Ingelheim pharmaceutical fortune. China and Hong Kong ranked third, with 32 new billionaires combined ...